Acquired resistance, on the other hand, can develop during treatment due to adaptive immune evasion, such as upregulation of alternative immune checkpoints (e.g., LAG-3, TIGIT) or depletion of effector T cells in the tumor microenvironment. Here, LAG3 is linked to neoplasm.